New developments in autoimmune diseases

4 February 2025

A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.

The global market for autoimmune disease therapeutics is forecast to generate $185 billion by 2029, growing at a CAGR’23-‘29 of 3.7%, driven by the increasing prevalence of autoimmune diseases and immune-related secondary disorders, multiple new product launches, and rising cost for treatments, according to iHealthcare Analysts.

Autoimmune diseases encompass a wide range of conditions including ankylosing spondylitis, atopic dermatitis, Crohn’s disease, irritable bowel diseases (IBD), multiple sclerosis (MS), psoriasis, psoriatic arthritis, rheumatoid arthritis (RA), nasal polyps, systemic lupus erythematosus (SLE), ulcerative colitis (UC), and urticaria. All leading pharma companies – AbbVie (NYSE: ABBV), AstraZeneca (LSE: AZN), Biogen (Nasdaq: BIIB), Bristol Myers Squibb (NYSE: BMY), Eli Lilly (NYSE: LLY), GSK (LSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck & Co (NYSE: MRK), Novartis (NOVN: VX), Pfizer (NYSE: PFE), Roche (ROG: SIX), Sanofi (Euronext: SAN) and Takeda (TYO: 4502) - market autoimmune products and have been actively licensing/acquiring products to expand their global foothold in this lucrative market.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK